Effects of different doses of metformin on bone metabolism and bone mineral density in elderly male patients with type 2 diabetes

Abstract

Abstract:

AIM: To observe the effect of different doses of metformin on bone metabolism and bone mineral density in elderly male patients with type 2 diabetes. METHODS: 102 untreated elderly male patients with type 2 diabetes were randomly divided into 3 groups. 3 groups were given low doses of metformin group (1 g/d, n=34), medium doses of metformin group (1.5 g/d, n=34) and high doses of metformin group (2 g/d, n=34). Phase of treatment lasted for 3 months. The levels of bone mineral density (BMD) of lumbar L2-4 and the femoral neck, serum bone specific alkaline phosphatase (BAP), blood gla protein (BGP), Tartrate Resistant Acid Phosphatase (TRACP), osteoprotegrin (OPG), fasting blood glucose (FBG) and hemoglobin A1C (HbA1C) were measured before treatment, 1 month and 3 months after administration. RESULTS:The levels of FBP and HbA1C in 3 groups were decreased significantly after treatment (P<0.05), but there was not significant difference among 3 groups (P>0.05). The indicators of bone metabolism TRACP and OPG in 3 groups reflected no significant change before and after treatment (P>0.05); BGP and BAP which reflected indicators of bone turnover and formation were increased after treatment, there was significant difference among 3 groups (P<0.05). The levels of BGP and BAP in the medium doses and the high doses of metformin groups was higher than counterpart in low doses of metformin group (P<0.05), there were significant differences among groups. But the levels of BGP and BAP in the medium and high doses of metformin group were not obvious difference over the same period (P>0.05). After 12 weeks of treatment, the levels of BMD in 3 groups were increased, there was statistical significance among groups (P<0.05). The levels of BMD in the medium doses and the high doses of metformin groups was higher than counterpart in low doses of metformin group (P<0.05), there were significant differences among groups. But the levels of BMD in the medium and high doses of metformin group were not obvious difference over the same period (P>0.05). CONCLUSION:Metformin not only can regulate the levels of blood glucose in elderly male with type 2 diabetes, but also improve the BMD of patients. This effect may depend on promoting bone formation, and curative effects have a certain dose of relevance.

Key words: metformin, type 2 diabetes, bone specific alkaline phosphatase, tartrate resistant acid phosphatase, bone mineral density

CLC Number:

R587

SHI Dejun, LIU Yi. Effects of different doses of metformin on bone metabolism and bone mineral density in elderly male patients with type 2 diabetes[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(9): 1045-1049.

References

［1］裴育，巴建明. 1型和2型糖尿病与骨质疏松症的关系［J］. 中华糖尿病杂志，2016，23(1): 12-14.
［2］王覃，陈德才. 糖尿病对骨质疏松症的影响及其机制［J］. 中华糖尿病杂志，2016，23(1): 5-7.
［3］Vestergard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes a meta-analysis ［J］. Osteoporo Int, 2007, 18(2): 427-444.
［4］Tolosa MJ, Chuguransky SR, Sedlinsky C, et al. Insulin-deficient diabetes-induced bone microarchitecture alteration are associated with a decrease in the osteogenic potential of bone marrow progenitor cells: preventive effects of metformin ［J］. Diabetes Res Clin Pract, 2013, 101(2): 177-186.
［5］Fontaine LJ, Chen C, Hunt N, et al. Type 2 diabetes and metformin influence on fracture healing in an experimental rat model ［J］. J Foot Ankle Surg, 2016, 55(5): 955-960.
［6］Zhen D, Chen Y, Tang X. Metformin reverses the deleterious effects of high glucose on osteobalst function ［J］. J Diabetes Complications,2010, 24(5): 334-344.
［7］Mai QG, Zhang ZM, Xu S, et al. Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblast and ovariectomized rats ［J］. J Cell Biochem, 2011, 112(10): 2902-2909.
［8］UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes ［J］. Lancet, 1998, 352(9131): 854-865.
［9］Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial ［J］. Am J Med, 1997,103(6): 491-497.
［10］ Zinman B, Haffner SM, Herman WH, et al. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes ［J］. J Clin Endocrinol Metab, 2010, 95(1): 134-142.
［11］魏开惠，王振华. 二甲双胍对2型糖尿病患者骨代谢的影响［J］. 实用临床医药杂志，2015，19(13): 117-118.
［12］Kasai T, Bandow K, Suzuki H, et al. Osteoblast differentiation is functionally associated with decreased AMP kinase activity ［J］. J Cell Physiol, 2009, 221(3): 740-749.
［13］Shu A, Yin MT, Stein E, et al. Bone structure and turnover in type 2 diabetes mellitus ［J］. Osteoporos Int, 2012, 23(2): 635-641.
［14］Schurman L, Mccarthy AD, Sedlinsky C, et al. Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells ［J］. Exp Clin Endocrinol Diabetes, 2008, 116(6): 333-340.
［15］Shah M, Kola B, Bataveljic A, et al. AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass ［J］. Bone, 2010, 47(2): 309-319.
［16］Jang WG, Kim EJ, Bae KN, et al. Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of Runx2 ［J］. Bone, 2011, 48(4): 885-893.

[1]	MA Yan, TIAN Gaopeng, SHI Xingwen, SUN Ting, XIE Jingjing, ZHEN Donghu. Correlation between 25(OH)D and metabolically related fatty liver in T2DM population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1018-1026.
[2]	MA Xiankang, YANG Lixia, CUI Yangyang, MI Denghai. Angelica polysaccharides improve hepatic endoplasmic reticulum stress by inhibiting the expression of GRP78, p-PERK and p-Eif2α in diabetic KK-Ay mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 926-936.
[3]	HOU Ruiying, GUO Lige, JIAO Weijie, DU Lei, WU Guiyue, ZHAO Xu. Effects of Xiaokeshu recipe on levels of serum inflammatory factors in type2 diabetic rats and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 377-382.
[4]	ZHAO Shifeng, SONG Xiangming, YAO Jianping. Tirzepatide: A new glucagon-like peptide-1 receptor/glucose-dependent insulinotropic peptide receptor dual agonist [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 220-227.
[5]	WANG Jie, LI Long, CHEN Feng, LIU Shengfei. Research progress of metformin in the pathogenesis of pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 235-240.
[6]	ZHAO Yangting, CHEN Chongyang, PAN Binjing, LV Xiaoyu, LIU Jingfang. Trimethylamine N-oxide: the potential target for osteoporosis treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1161-1167.
[7]	DU Xiaoyu, LI Yumeng, WU Huizhen, QIU Bo. Pharmacological and clinical evaluation of Dorzagliatin in the treatment of type 2 diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1177-1183.
[8]	CAI Jing, PAN Binjing, LIU Jingfang. Research progress on the relationship between hypoglycemic drugs and sarcopenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 101-108.
[9]	WANG Xin, LIU Weiying, WU Chen, KAI Jinjun, LIANG Xuejie, CHANG Yingxuan. Metformin regulates AMPK/SREBP-1 pathway and its clinical application [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1049-1054.
[10]	ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen. Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074.
[11]	LU Senlin, LIU Xinyuan, WANG Jili, HUANG Xiaofei. Research progress of virus-mediated gene therapy in type 2 diabetes mellitu [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 800-807.
[12]	WANG Zhen, QUAN Haiyan, HONG Chenliang, YUAN Lijialong, QIN Xuping. Swimming improves renal function of diabetic mice by promoting autophagy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 632-638.
[13]	ZENG Xiaofan, XU Yiqi, LIU Shu, WU Qian, LI Zibao, HE Junjun, JIN Yuelong, ZHAO Yongli, HE Chunling, GAO Jialin. Retrospectively analysis of the effect of low-dose aspirin on primary prevention of non-fatal myocardial infarction and cerebral infarction in patients with type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 665-671.
[14]	SHAO Xi, YU Yanan, HUANG Yuhan, WANG Xiaotong, LING Hongwei, LV Dongmei, WANG Tao. Predictive factors associated with weight response to exenatide in patients with type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 287-294.
[15]	DAI Hongyu, YANG Kun, HU Ruchun, ZHOU Hongmei, MA Peimin, HAO Qian. Duration time and effectiveness of 0.25%ropivacaine for sciatic nerve block in patients with diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1278-1284.